The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Celgene Europe B.V.EU/1/22/1631/001

Main Information

Trade NameBreyanzi
Active SubstancesLisocabtagene Maraleucel
Dosage FormDispersion for infusion
Licence HolderCelgene Europe B.V.
Licence NumberEU/1/22/1631/001

Group Information



License statusAuthorised
Licence Issued04/04/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back